Genomics-based analyses of urinary ctDNA have emphasized the somatic mutations linked to the primary tumors of BC patients, such as the PIK3CA and TP53 mutated genes, offering the non-invasive probing and real-time monitoring of BC relapse [164]. Here, TP53 is linked to breast cancer.